IsoRay – Consensus Indicates Potential 291.9% Upside

Broker Ratings

IsoRay found using ticker (ISR) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 1.6 and 1.25 with a mean TP of 1.45. Now with the previous closing price of 0.37 this indicates there is a potential upside of 291.9%. The 50 day MA is 0.57 while the 200 day moving average is 0.64. The market cap for the company is $26m. You can visit the company’s website by visiting:

Share on Stocktwits

Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray was founded in 1998 and is headquartered in Richland, Washington.

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index